Zydus Pharmaceuticals gets USFDA nod for OCD treatment drug

The company has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, 50 mg and 75 mg, Zydus Cadila said in a BSE filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news